Current and Future Strategies for Targeting the Endothelin Pathway in Cardiovascular Disease

Combinations of endothelin receptor blockers with other drugs, including phosphodiesterase-5 inhibitors and sodium–glucose co-transporter-2 antagonists, may drive synergistic benefits with the prospect of alleviating side effects.